Christopher McLeod

Christopher McLeod is the Managing Partner at Elm Street Ventures. He attended MIT Sloan School of Management and Yale University. Throughout his career, Christopher McLeod has demonstrated expertise in growing companies through strategic collaborations, innovative marketing, and new product development. Mr. McLeod served as President and Chief Executive Officer of 454 Life Sciences from February 2005 through September 2011, and managed the integration with Roche Diagnostics following its acquisition in 2007. He led the development, manufacturing and marketing of the company's innovative DNA sequencing technology and products, which are sold to thousands of research laboratories worldwide. Previously, he served as Executive Vice President of CuraGen from November 1999, where he oversaw bioinformatics, strategic business development, and collaborative research, including the negotiation of strategic partnerships with Abgenix, Bayer and TopoTarget A/S. Prior to joining CuraGen, Mr. McLeod spent over two years as Chief Executive Officer of Havas Interactive (formerly Cendant Software), a leading international software developer with such leading brands as Blizzard, Serra, and Knowledge Adventure, whose annual revenues increased in excess of 60 percent to over $500 million during his tenure. Previously, Mr. McLeod served as Executive Vice President and Director at CUC International where he was President of the CompuCard division, marketing affinity membership programs with partners including Citibank, Sears, Bank One and Chase. Mr. McLeod earned his B.S. Magna Cum Laude with a dual major in economics and engineering and applied science from Yale University and his M.S. in management from the Sloan School of Management at Massachusetts Institute of Technology. Mr. McLeod serves on the boards of Sacred Heart University and the CT Yankee Council, Boy Scouts of America, and the North American Executive Board of the Sloan School of Management at MIT.